NCT05352347View on ClinicalTrials.gov

Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

1,134

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions
COVID-19 Pneumonia
Interventions
DRUG

NuSepin® 0.2 mg/kg

NuSepin® 0.2 mg/kg in 100mL NS bid

DRUG

NuSepin® 0.4 mg/kg

NuSepin® 0.4 mg/kg in 100mL NS bid

DRUG

Placebo

Normal saline (NS) 100mL bid

Trial Locations (1)

21565

RECRUITING

Gachon University Gil Medical Center, Incheon

Sponsors

Lead Sponsor

Shaperon
All Listed Sponsors
lead

Shaperon

INDUSTRY